Department of Radiation Medicine, Georgetown University Hospital Introduction Department of Biostatistics, Georgetown University
|
|
- Marilynn Lyons
- 6 years ago
- Views:
Transcription
1 Technology in Cancer Research and Treatment ISSN Volume 9, Number 5, October 2010 Adenine Press (2010) A Pilot Study of Intensity Modulated Radiation Therapy with Hypofractionated Stereotactic Body Radiation Therapy (SBRT) Boost in the Treatment of Intermediate- to High-Risk Prostate Cancer Clinical data suggest that large radiation fractions are biologically superior to smaller fraction sizes in prostate cancer radiotherapy. The CyberKnife is an appealing delivery system for hypofractionated radiosurgery due to its ability to deliver highly conformal radiation and to track and adjust for prostate motion in real-time. We report our early experience using the CyberKnife to deliver a hypofractionated stereotactic body radiation therapy (SBRT) boost to patients with intermediate- to high-risk prostate cancer. Twenty-four patients were treated with hypofractionated SBRT and supplemental external radiation therapy plus or minus androgen deprivation therapy (ADT). Patients were treated with SBRT to a dose of 19.5 Gy in 3 fractions followed by intensity modulated radiation therapy (IMRT) to a dose of 50.4 Gy in 28 fractions. Quality of life data were collected with American Urological Association (AUA) symptom score and Expanded Prostate Cancer Index Composite (EPIC) questionnaires before and after treatment. PSA responses were monitored; acute urinary and rectal toxicities were assessed using Common Toxicity Criteria (CTC) v3. All 24 patients completed the planned treatment with an average follow-up of 9.3 months. For patients who did not receive ADT, the median pre-treatment PSA was 10.6 ng/ml and decreased in all patients to a median of 1.5 ng/ml by 6 months post-treatment. Acute effects associated with treatment included Grade 2 urinary and gastrointestinal toxicity but no patient experienced acute Grade 3 or greater toxicity. AUA and EPIC scores returned to baseline by six months post-treatment. Hypofractionated SBRT combined with IMRT offers radiobiological benefits of a large fraction boost for dose escalation and is a well tolerated treatment option for men with intermediate- to high-risk prostate cancer. Early results are encouraging with biochemical response and acceptable toxicity. These data provide a basis for the design of a phase II clinical trial. Key words: Prostate Cancer; SBRT; IMRT; CyberKnife; EPIC; quality of life; Acute toxicity; Common Toxicity Criteria (CTC). Introduction The importance of local control in prostate cancer is clear; local failures from radiotherapy can lead to higher distant failure rates (1) and morbidity resulting from uncontrolled local disease can be significant including urinary obstruction, bleeding and pain. Achieving improved local control within the prostate Eric K. Oermann 1 Rebecca S. Slack, M.S. 2 Heather N. Hanscom 1 Sue Lei 1 Simeng Suy, Ph.D. 1 Hyeon U. Park, Ph.D. 1 Joy S. Kim 1 Benjamin A. Sherer 3 Brian T. Collins, M.D. 1 Andrew N. Satinsky, M.D. 1 K. William Harter, M.D. 1 Gerald P. Batipps, M.D. 3 Nicholas L. Constantinople, M.D. 3 Stephen W. Dejter, M.D. 3 William C. Maxted, M.D. 3 James B. Regan, M.D. 3 John J. Pahira, M.D. 3 Kevin G. McGeagh, M.D. 3 Reena C. Jha, M.D. 4 Nancy A. Dawson, M.D. 5 Anatoly Dritschilo, M.D. 1 John H. Lynch, M.D. 3 Sean P. Collins, M.D., Ph.D. 1 * 1 Department of Radiation Medicine, Georgetown University Hospital 2 Department of Biostatistics, Georgetown University 3 Department of Urology, Georgetown University Hospital 4 Department of Radiology, Georgetown University Hospital 5 Department of Medical Oncology, Georgetown University Hospital *Corresponding Author: Sean P. Collins, M.D., Ph.D SPC9@georgetown.edu 453
2 454 Oermann et al. (A) (B) (C) Critical Structure Vx Gy Vx Gy Allowed Vx variations constraint Minor Major Rectum 19.5 Gy < 1 cc V19.5 Gy 1 cc, but < 2 cc Bladder 19.5 Gy < 10 cc V19.5 Gy 10 cc, V19.5 Gy > 2 cc V19.5 Gy > 20 cc but < 20 cc Penile bulb 15 Gy < 50% V15 Gy 50%, but < 75% V15 Gy > 50% Membranous urethra Sigmoid colon and other bowel 18 Gy < 50% V18 Gy 50%, but < 75% 15 Gy < 1 cc V15 Gy 1 cc, but < 2 cc V18 Gy > 75% V15 Gy > 2 cc Figure 1: SBRT treatment planning axial (A) and sagittal (B) computed tomography images demonstrating the CTV (red), PTV1 expansion (dark blue), bladder (orange), rectum (yellow), and membranous urethra (pink). The prescription isodose lines are shown at 84% (light blue), 70% (yellow) and 50% (green). (C) Summary of SBRT dose volume constraints for the critical structures where Vx Gy denotes the volume of the structure receiving a dose of x Gy. therefore carries promise of reducing the sequelae attributable to uncontrolled local disease as well as improving survival. Radiation Oncologists efforts to improve local control, by optimizing the therapeutic ratio, have been directed toward limiting the high dose volume to the prostate while escalating the dose within that volume. Along these lines, three-dimensional conformal radiation treatment (3DCRT) has increased local control rates with lower complication rates when compared to standard external beam techniques (2, 3). Similarly, intensity modulated radiation therapy (IMRT) has allowed dose-escalation to 81 Gy with acceptable levels of complications (4). Yet, with 8-year biochemical relapse-free rates of 78% and 67% for intermediate- and high-risk patients, it is clear that even higher doses may be required to eradicate prostate cancer (5-7). Recent data suggest that large radiation fraction sizes are radio-biologically favorable over smaller fraction sizes in prostate cancer radiotherapy (8). High dose rate (HDR) brachytherapy as a boost to external beam radiation therapy (EBRT) has shown promise in this regard. Several studies have reported 5-year biochemical control rates of 93-98% (9-11), 89-93% (9-11) and 69-83% (7, 9-11) for low-, intermediate-, and high-risk prostate cancer with 5-year cause-specific survival rates of 96-98% independent of risk (7, 9-12).
3 IMRT with SBRT Boost for Localized Prostate Cancer 455 In an effort to further improve patient tolerance in comparison to HDR brachytherapy, we have examined the use of CyberKnife stereotactic radiosurgery as a boost to IMRT for the treatment of patients with intermediate- and highrisk clinically localized prostate cancer. The CyberKnife uses hundreds of non-isocentric beams to deliver a highly conformal radiation dose with steep dose gradients (13) which can be used to limit dose and toxicity to surrounding structures. Unlike HDR brachytherapy treatment, the CyberKnife does not require anesthesia or hospitalization. When compared to intensity modulated radiation therapy, dosimetric studies have shown that CyberKnife plans show rapid dose fall-off rates from the prostate with significantly better conformity than IMRT plans at a relatively greater dose inhomogeneity (14). This relative inhomogeneity can be taken advantage of to allow for HDR-like dose escalation within the prostatic peripheral zone (15). The CyberKnife incorporates a dynamic tracking system consisting of an orthogonal pair of diagnosticquality x-ray imaging devices and software that can locate fiducials implanted in or near the target. This provides updated position information in six-dimensions (3 translations combined with roll, pitch and yaw rotations) for targeting of the therapeutic beam during treatment and allows for correction of intrafraction motion (16). We report on the use of CyberKnife SBRT as a homogeneous hypofractionated boost to IMRT for the treatment of 24 prostate cancer patients. Grade Diarrhea Increase of < 4 stools per day Increase of 4-6 stools per day; not interfering with ADL Increase 7 stools per day; hospitalization; interfering with ADL Life threatening consequences Colitis Asymptomatic Proctitis Rectal discomfort not requiring treatment Abdominal pain with mucus and/or blood in stools Medical treatment indicated, no interference with ADL Abdominal pain, fever, ileus; peritoneal signs Surgical intervention indicated; interference with ADL Perforation or other complication requiring surgical intervention Life threatening consequences Rectal bleeding Hematuria Dysuria Urinary Incontinence Mild, intervention not indicated Microscopic only Mild pain not interfering with function Occasional, pads not indicated Symptomatic and medical intervention or minor cauterization indicated Gross bleeding; medical intervention indicated Moderate pain; pain or analgesics interfering with function, but not interfering with ADL Spontaneous, pads indicated Transfusion or surgical intervention required Transfusion or surgical intervention required Severe pain; pain or analgesics severely interfering with ADL Interfering with ADL; intervention indicated Life threatening consequences Life threatening consequences; open surgery indicated; necrosis Disabling Surgical intervention indicated Urinary Frequency/ Urgency Increase up to 2x normal Increase > 2x normal but less than hourly More than hourly; catheter indicated Urinary retention Dribbling Hesitancy requiring medication More than daily catheterization indicated; urological intervention indicated Life-threatening consequences Fatigue Mild fatigue over baseline Moderate fatigue causing difficulty performing ADL Severe fatigue interfering with ADL Disabling Figure 2: Summary of acute toxicity scoring using the Common Toxicity Criteria version 3.0 guidelines.
4 456 Oermann et al. Methods Patient Selection Patients eligible for inclusion in this study had histologically confirmed adenocarcinoma of the prostate, clinical stage T1c-T3b, and a baseline AUA score of less than 20. Exclusion criteria included clinically involved lymph nodes on imaging; distant metastases on bone scan; prior pelvic radiotherapy or prior radical prostate surgery. Androgen deprivation therapy was administered at the discretion of the treating Urologist. Institutional IRB approval was obtained for the treatment protocol. All patients signed a consent form. SBRT Treatment Planning and Delivery All patients had at least four gold fiducials placed in the prostate prior to treatment planning: two at the apex and two at the base. To allow for fiducial stabilization, planning imaging was performed at least 7 days after fiducial placement. Patients underwent 1.5 T MR imaging followed shortly thereafter by a thin cut (1.25 mm) CT scan. Both scans were performed with an empty bladder. Patients were advised to adhere to a low-gas, low-motility diet, starting at least five days prior to all treatment planning imaging and treatment delivery. They were nothing by mouth (NPO) the night before and an enema was administered 1-2 hours prior to imaging and treatment. Fused CT and MR images were used for treatment planning. The clinical target volume (CTV) included the prostate, areas of radiographic extracapsular extension and the proximal seminal vesicles to the point where the left and right seminal vesicle separate (Figure 1A & B). The SBRT planning target volume (PTV1) equaled the CTV expanded 3 mm posteriorly and 5 mm in all other dimensions. The prescription dose was 19.5 Gy to the PTV1 delivered in three fractions of 6.5 Gy over 3-5 days with some patients receiving treatments on 3 consecutive days and some patients receiving treatment on alternating days. The volume of the PTV1 receiving 19.5 Gy, termed the V19.5 Gy, was to be at least 95%. Variations of the V19.5 Gy that were less than 95%, but greater than or equal to 90%, were considered minor variations; whereas major variations occurred when the V19.5 Gy was less than 90%. The prescription isodose line was limited to > 75% which limited the maximum prostatic urethra dose to 133% of the prescription dose. For the CTV, at least 95% of the volume was to receive 21 Gy (V21 Gy). Variations were considered minor if the V21 Gy was less than 95%, but greater than or equal to 90%; whereas variations less than 90% were considered major. The rectum, bladder, penile bulb and membranous urethra were contoured structures Table I Pre-treatment patient characteristics. # Race PSA (ng/ml) T Stage Gleason Score Prostate Volume (cc) Risk Group AUA SHIM ADT 1 AA c Intermediate 12 3 No 2 C 2.5 2a Intermediate 13 1 Yes 3 AA 4.4 1c Intermediate 0 15 No 4 C 4.8 2a Intermediate 3 25 No 5 AA 6.2 1c Intermediate No 6 AA 6.5 1c Intermediate 8 4 No 7 C 6.6 2b Intermediate 8 11 No 8 AA 7.9 1c Intermediate 2 1 Yes 9 C 8.2 1c Intermediate 5 2 Yes 10 AA 10 1c Intermediate 9 9 No 11 AA 10 1c Intermediate 0 4 No 12 AA c Intermediate 4 20 No 13 C 14 1c Intermediate 5 9 No 14 C c High 7 1 Yes 15 C c High 8 20 No 16 AA 25 1c High 0 15 No 17 C 26 1c High 16 1 Yes 18 AA 3.9 1c High 9 3 Yes 19 AA 5.7 1c High 2 23 Yes 20 C 7.7 2b High 6 2 Yes 21 C c High 12 1 Yes 22 AA c High 2 1 No 23 AA c High 5 15 No 24 AA 4.7 1c High 9 16 Yes
5 IMRT with SBRT Boost for Localized Prostate Cancer 457 Table II Treatment characteristics. (A) Shown are the mean of the treatment planning parameters (percent target coverage, prescription isodose line and critical structure dose/volume results), the percent of treatment plans that met the protocol s goals and the percent that were minor and major variations from protocol. Percentage of rectum receiving 50%, 80%, 90% and 100% of the prescription dose is reported as rectum V50, V80, V90 and V100, respectively. (B) Summary of the extent of minor and major treatment variations. The treatment planning goals are in parentheses. A Treatment Characteristic Mean Per Protocol Minor Variations Major Variations CTV 95% 70% 25% 5% PTV1 95% 87% 13% 0% Isodose Line 79% 100% 0% 0% Bladder (V19.5Gy) 8.1 cc 92% 8% 0% Penile Bulb (V15Gy) 8.0% 100% 0% 0% Mem. Urethra (V18Gy) 37% 87% 13% 0% Rectum (V19.5Gy) 0.8 cc 92% 8% 0% Rectum V50 47% NA NA NA Rectum V80 13% NA NA NA Rectum V90 6% NA NA NA Rectum V % NA NA NA B Patient PTV1 (>95%) CTV (>95%) Rectum (<1 cc) Bladder (<10 cc) Mem. Urethra (<50%) cc 51% % 7 52% % 92.4% cc 13 53% % % 93.5% 10.7 cc % % % 91.0% cc and evaluated with dose-volume histogram analysis during treatment planning using Multiplan (Accuray Inc., Sunnyvale, CA) inverse treatment planning. The neurovascular bundles and prostatic urethra were not contoured as planned due to poor visualization on the 1.5 T treatment planning MRI. The rectal contour included the lumen and rectal wall from the anal canal to the rectosigmoid flexure. The bladder and bowel contours were the larger composites of the MRI and CT volumes. Sigmoid colon and other bowel adjacent to the PTV1 were contoured if present. Our rectal dose volume histogram (DVH) goals were <50% rectal volume receiving 50% of the prescribed dose, <20% receiving 80% of the dose, <10% receiving 90% of the dose, and <5% receiving 100% of the dose (17). Dose and volume constraints to the critical structures are summarized in Figure 1C. Table III Summary of CTC graded acute gastrointestinal (GI) and genitourinary (GU) toxicities. Gastrointestinal Toxicity IMRT Pre- On- Treatment Treatment 1 Month 3 Month 6 Month Grade N (%) N (%) N (%) N (%) N (%) Diarrhea 0 21 (88) 13 (54) 18 (75) 18 (75) 19 (79) 1 3 (13) 10 (42) 5 (21) 6 (25) 5 (21) 2 0 (0) 1 (4) 1 (4) 0 (0) 0 (0) Proctitis 0 24 (100) 17 (71) 17 (71) 19 (79) 19 (79) 1 0 (0) 7 (29) 7 (29) 5 (21) 5 (21) 2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Rectal Bleeding 0 23 (96) 21 (88) 22 (92) 24 (100) 24 (100) 1 1 (4) 3 (13) 2 (8) 0 (0) 0 (0) 2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Highest GI 0 21 (88) 11 (46) 15 (63) 15 (63) 16 (67) 1 3 (13) 12 (50) 8 (33) 9 (38) 8 (33) 2 0 (0) 1 (4) 1 (4) 0 (0) 0 (0) Genitourinary Toxicity Hematuria 0 24 (100) 22 (92) 24 (100) 23 (96) 23 (96) 1 0 (0) 2 (8) 0 (0) 1 (4) 1 (4) 2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Dysuria 0 19 (79) 14 (58) 15 (63) 16 (67) 18 (75) 1 4 (17) 8 (33) 6 (25) 7 (29) 5 (21) 2 1 (4) 2 (8) 3 (13) 1 (4) 1 (4) Incontinence 0 21 (88) 22 (92) 20 (83) 22 (92) 21 (88) 1 1 (4) 0 (0) 2 (8) 1 (4) 2 (8) 2 2 (8) 2 (8) 2 (8) 1 (4) 1 (4) Urinary Frequency/ Urgency 0 24 (100) 12 (50) 21 (88) 22 (92) 22 (92) 1 0 (0) 12 (50) 3 (13) 2 (8) 2 (8) 2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Retention 0 11 (46) 11 (46) 8 (33) 8 (33) 14 (58) 1 12 (50) 10 (42) 15 (63) 15 (63) 9 (38) 2 0 (0) 3 (13) 1 (4) 1 (4) 1 (4) Highest GU 0 9 (38) 3 (13) 5 (21) 6 (25) 11 (46) 1 13 (54) 18 (75) 15 (63) 15 (63) 11 (46) 2 2 (8) 3 (13) 4 (17) 3 (13) 2 (8) The protocol was designed to deliver a total radiation dose to the PTV1 biologically equivalent to 92.1 Gy in 2 Gy fractions assuming an α/β ratio of 1.5 Gy. To achieve this, all patients were treated with IMRT immediately following SBRT. For all IMRT treatments fiducial guidance was used for set-up. The more generous PTV2 included a margin of 1.0 cm around the CTV except at the rectal interface where a margin of 0.5 cm was added. Daily doses of 1.8 Gy were delivered to the PTV2 5 days a week to a total dose of 50.4 Gy in 28 fractions. The minimum target dose constraint to the PTV2 was 49.5 Gy and the maximum target dose constraint was 53 Gy. In addition, 100% of the PTV2 was to receive at least 95% of the prescription dose and 5% of the volume was to receive no more than 105% of the prescription dose. For the bladder and rectum,
6 458 Oermann et al. Figure 3: Summary of patient quality of life: (A) SF-12 physical component (PC) score, (B) SF-12 mental component (MC) score, (C) AUA score and (D) SHIM score. The graphs show unadjusted changes in mean toxicity and QOL scores over time. SF-12 scores range from with higher values representing improved health status. AUA scores range from 0-35 with higher values representing worsening urinary symptoms. SHIM scores range from 0-25 with lower values representing worsening sexual function. Numbers above each time point indicate the number of observations contributing to the mean. the maximum dose constraint limit was 50 Gy, the fullvolume dose constraint limit was 30 Gy and no part of either volume received more than 55.5 Gy. Dose to the femoral heads was limited to 45 Gy. Follow-up Acute toxicity was defined as those events that presented and resolved within the first 6 months following completion of treatment. Toxicity was assessed pre-treatment, during treatment and at 1, 3 and 6 months using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version 3.0 (Figure 2) and the American Urological Association (AUA) symptom score (also known as International Prostate Symptom Score) (18). Quality of life (QoL) was assessed pretreatment and at follow-up visits using the Short Form-12 Health Survey (SF-12), the Expanded Prostate Cancer Index Composite (EPIC) questionnaire (19) and the Sexual Health Inventory for Men (SHIM) questionnaire (20). Statistical Methods A pilot protocol was written to test whether patients could have Cyberknife plans developed and delivered with no major treatment planning variations, with early stopping if there was 1 major variation in the first 10 patients. Toxicity and treatment planning variations have been tabulated. Differences in ongoing quality of life scores were compared to baseline using paired t-tests. Mean scores at baseline, 1, 3, and 6 months were presented graphically. Results From April 2008 to April 2009, 24 prostate cancer patients were accrued for the IRB approved protocol. The median patient age was 68.5 years (range, years). Similar numbers of Caucasians (C) and African Americans (AA) were enrolled reflecting the distribution of our normal patient population. Thirteen patients were intermediaterisk and eleven were high-risk using the D Amico Risk
7 IMRT with SBRT Boost for Localized Prostate Cancer 459 not receive ADT, the median pre-treatment PSA was 10.6 ng/ ml. Table I provides detailed patient characteristics. Table IIA provides a summary of the treatment characteristics. Minor protocol variations occurred in 50% of the patients, but these were small deviations from the planned treatment and likely of little clinical significance (Table IIB). One major variation from the treatment protocol occurred. In this case, the dose to the CTV was limited to maintain the rectal dose within protocol limits. Our rectal DVH goals were obtained in most patients. At an average follow-up of 9.3 months (range: months), the initial PSA response has been favorable. The median 6 month post-treatment PSA was 1.5 ng/ml for patients who did not receive ADT. Toxicity has been minimal with no Grade 3 or higher gastrointestinal (GI) or gastrourinary (GU) toxicities (Table III). Grade 2 toxicities included urinary symptoms requiring alpha blockers and bowel frequency/spasms requiring antidiarrheals. Figures III and IV present a summary of the changes in quality of life indicators over time. By six months posttreatment, the patients perceptions of their physical health (Figure 3A) and mental health (Figure 3B) had improved. In the case of mental health, this improvement was significant (p = 0.03; Table IV). At one month post-treatment the mean AUA toxicity scores had increased to a value of 10.7 from a baseline of 7.4 (p = 0.01; Figure 3C, Table IV). By 6-months post-treatment the mean AUA toxicity score had returned to baseline. Similarly, at one month post-treatment the mean SHIM scores had decreased to a value of 8.6 from a baseline of 10.9 (Figure 3D). Mean SHIM quality of life returned to baseline by 6 months (Table IV). As with the AUA and SHIM scores, the EPIC urinary and EPIC sexual scores decreased at one month and returned to baseline by 6 months (Figures IVA and IVC, Table IV). The mean EPIC bowel score decreased slightly at one month and six months (Figure IVB). However, the decrease at six months was not significant (Table IV). Discussion Figure 4: EPIC quality of life for (A) urinary, (B) bowel, and (C) sexual function. The graphs show unadjusted changes in mean QOL scores over time for each domain. EPIC scores range from with higher values representing a more favorable health-related QOL. Numbers above each time point indicate the number of observations contributing to the mean. Classification (21). Baseline median PSA was 9.1 ng/ml (range, ng/ml). Forty-two percent of patients received androgen deprivation therapy (ADT). For patients who did This study aimed at assessing the feasibility and safety of performing IMRT with CyberKnife SBRT boost for intermediate- to high-risk clinically localized prostate cancer. Hypofractionated SBRT boost was chosen for this study due to the potential benefits of hypofractionation (8) including radiobiologic dose escalation. In addition, SBRT does not require anesthesia and/or hospitalization expanding its potential utilization in the elderly prostate cancer patient population. Acute Grade 2 GU toxicities and GI toxicities were observed in 13% and 4% of patients, respectively. There were no toxicities
8 460 Oermann et al. Table IV Overview of patient quality of life (QoL). QoL Measure Pre-Treatment 1 Month 3 Month 6 Month SF-12 PCS 43.8 (0 61.6) 43.2 (0 61.5) 43.4 (0 59.5) 48.7 ( ) SF-12 MCS 42.9 (0 64.3) 46.4 (0 63.7) 49.1 (0 61.7) 52.9 ( ) AUA 7.4 (0 24) 10.7 (0 22) 7.7 (0 16) 7.1 (0 25) SHIM 10.9 (1 25) 8.6 (1 25) 10.8 (1 25) 11.9 (1 25) EPIC Urinary 90.1 ( ) 82.0 ( ) 89.4 ( ) 89.6 ( ) EPIC Bowel 97.1 ( ) 93.6 ( ) 96.1 (75 100) 92.6 ( ) EPIC Sexual 51.5 ( ) 45.0 (0 91.7) 50.5 ( ) 51.5 ( ) The table shows unadjusted changes in mean toxicity and QOL scores over time. SF-12 scores range from with higher values representing improved health status. AUA scores range from 0-35 with higher values representing worsening urinary symptoms. SHIM scores range from 0-25 with lower values representing worsening sexual function. EPIC scores range from with higher values representing a more favorable health-related QOL. Bold numbers designate time points at which scores differed significantly from pre-treatment (p < 0.05). greater than Grade 2. In comparison, published brachytherapy boost publications have reported acute Grade 2 and 3 GU toxicity rates ranging from % and %, respectively; reported Grade 2 GI toxicities for HDR boost have ranged from 3.9-7% (16-19). Table V provides an overview of observed acute toxicities for prostate boost publications reporting with the CTC criteria. Our results appear comparable to others. Preliminary quality of life also appears favorable with AUA, SHIM and EPIC scores returning to baseline by six months after treatment. A study of prostate cancer patient quality of life using EPIC examined patients treated with external beam radiation therapy (EBRT) alone, EBRT plus low dose rate (LDR) brachytherapy and LDR brachytherapy alone (22). At six months, EPIC scores had not returned to baseline. Summary Hypofractionated SBRT combined with IMRT is a promising new treatment option for men with intermediate- and high-risk prostate cancer. Acute toxicity in this pilot study was minimal and the treatment appears well Table V Summary of brachytherapy boost publications reporting CTC acute toxicity. GU Toxicity Grade Hurwitz et al. (23) EBRT + LDR Valero et al. (24) EBRT + HDR Martin et al. (25) 3DCRT + HDR Sato et al. (26) HDR + EBRT Current Study IMRT + CyberKnife Hematuria 2 0% 0% 3 0% 0% Dysuria 2 5% 2.2% 4% 3 3% 0% 0% Incontinence 2 5% 0% 0% 3 0% 0% 0% Urinary Frequency 2 16% 6% 0% Urgency 3 2% 0% 3.9% 0% Retention 2 7% 0.7% 13% 3 0% 3.0% 0% Overall % 5.5% 13% 3 3.0% 3.9% 1.8% 0% GI Toxicity Diarrhea 2 2.2% 4% 3 0.7% 0% Proctitis 2 7% 4.5% 0% 3 0% 0% 0% Rectal Bleeding 2 0% 0% 3 0% 0% Overall 2 7.8% 3.8% 4% 3 0.7% 0% 0% 0% A indicates the value was not reported in that publication.
9 IMRT with SBRT Boost for Localized Prostate Cancer 461 tolerated with little impact on quality of life. Early results suggest encouraging biochemical response with low toxicity. These data provide a basis for the design of a phase II clinical trial. Conflicts of Interest:. Acknowledgements We acknowledge Robert Meier, M.D, Solomon B. Makgoeng, Kathryn Taylor, Ph.D. and Arnold L. Potosky, Ph.D. for helpful discussions. We gratefully acknowledge the editorial assistance of Pam Commike, Ph.D., Accuray Incorporated. The views expressed here are entirely the authors ; Accuray did not provide assistance with data collection, compilation, or interpretation. References 1. Fuks, Z., Leibel, S. A., Wallner, K. E., Begg, C. B., Fair, W. R., Anderson, L. L., Hilaris, B. S., Whitmore, W. F. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys 21, (1991). 2. Dearnaley, D. P., Khoo, V. S., Norman, A. R., Meyer, L., Nahum, A., Tait, D., Yarnold, J., Horwich, A. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 353, (1999). 3. Beard, C. J., Kaplan, I. D., Coleman, C. N. The challenge for conformal therapy for prostate cancer. Int J Radiat Oncol Biol Phys 26, (1993). 4. Zelefsky, M. J., Chan, H., Hunt, M., Yamada, Y., Shippy, A. M., Amols, H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176, (2006). 5. Kuban, D. A., Levy, L. B., Cheung, M. R., Lee, A. K., Choi, S., Frank, S., Pollack, A. Long-term Failure Patterns and Survival in a Randomized Dose-Escalation Trial for Prostate Cancer. Who Dies of Disease? Int J Radiat Oncol Biol Phys, In Press. 6. Stone, N. N., Potters, L., Davis, B. J., Ciezki, J. P., Zelefsky, M. J., Roach, M., Shinohara, K., Fearn, P. A., Kattan, M. W., Stock, R. G. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 73, (2009). 7. Martinez, A. A., Gustafson, G., Gonzalez, J., Armour, E., Mitchell, C., Edmundson, G., Spencer, W., Stromberg, J., Huang, R., Vicini, F. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 53, (2002). 8. Fowler, J. F. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 44, (2005). 9. Phan, T. P., Syed, A. M., Puthawala, A., Sharma, A., Khan, F. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol 177, ; discussion 127 (2007). 10. Demanes, D. J., Rodriguez, R. R., Schour, L., Brandt, D., Altieri, G. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy s 10-year results. Int J Radiat Oncol Biol Phys 61, (2005). 11. Galalae, R. M., Martinez, A., Mate, T., Mitchell, C., Edmundson, G., Nuernberg, N., Eulau, S., Gustafson, G., Gribble, M., Kovacs, G. Long-term outcome by risk factors using conformal high-doserate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58, (2004). 12. Hiratsuka, J., Jo, Y., Yoshida, K., Nagase, N., Fujisawa, M., Imajo, Y. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Int J Radiat Oncol Biol Phys 59, (2004). 13. Webb, S. Conformal intensity-modulated radiotherapy (IMRT) delivered by robotic linac--testing IMRT to the limit? Phys Med Biol 44, (1999). 14. Hossain, S., Xia, P., Huang, K., Descovich, M., Chuang, C., Gottschalk, A. R., Roach, M., III, Ma, L. Dose Gradient Near Target- Normal Structure Interface for Nonisocentric CyberKnife and Isocentric Intensity-Modulated Body Radiotherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys, In Press. 15. Fuller, D. B., Naitoh, J., Lee, C., Hardy, S., Jin, H. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 70, (2008). 16. Xie, Y., Djajaputra, D., King, C. R., Hossain, S., Ma, L., Xing, L. Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 72, (2008). 17. King, C. R., Brooks. J. D., Gill, H., Pawlicki, T., Cotrutz, C., Presti, J. C., Jr. Stereotactic Body Radiotherapy for Localized Prostate Cancer: Interim Results of a Prospective Phase II Clinical Trial. Int J Radiat Oncol Biol Phys 73, (2009). 18. Barry, M. J., Fowler, F. J., Jr., O Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148, ; discussion 1564 (1992). 19. Wei, J.T., Dunn, R. L., Litwin, M. S., Sandler, H. M., Sanda, M. G. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56, (2000). 20. Rosen, R. C, Cappelleri, J. C., Gendrano, N, III. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res 14, (2002). 21. D Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Blank, K., Broderick, G. A., Tomaszewski, J. E., Renshaw, A. A., Kaplan, I., Beard, C. J., Wein, A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama 280, (1998). 22. Sanda, M. G., Dunn, R. L., Michalski, J., Sandler, H. M., Northouse, L., Hembroff, L., Lin, X., Greenfield, T. K., Litwin, M. S., Saigal, C. S., Mahadevan, A., Klein, E., Kibel, A., Pisters, L. L., Kuban, D., Kaplan, I., Wood, D., Ciezki, J., Shah, N., Wei, J. T. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358, (2008). 23. Hurwitz, M. D., Halabi, S., Ou, S. S., McGinnis, L. S., Keuttel, M. R., Dibiase, S. J., Small, E. J. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB Int J Radiat Oncol Biol Phys 72, (2008). 24. Valero, J., Cambeiro, M., Galan, C., Teijeira, M., Romero, P., Zudaire, J., Moreno, M., Ciervide, R., Aristu, J. J., Martinez-Monge R. Phase II Trial of Radiation Dose Escalation with Conformal External Beam Radiotherapy and High-Dose-Rate Brachytherapy
10 462 Oermann et al. Combined with Long-Term Androgen Suppression in Unfavorable Prostate Cancer: Feasibility Report. Int J Radiat Oncol Biol Phys 76, (2009). 25. Martin, T., Roddiger, S., Kurek, R., Dannenberg, T., Eckart, O., Kolotas, C., Heyd, R., Rogge, B., Baltas, D., Tunn, U., Zamboglou, N. 3D conformal HDR brachytherapy and external beam irradiation com- bined with temporary androgen deprivation in the treatment of localized prostate cancer. Radiother Oncol 71, (2004). 26. Sato, M., Mori, T., Shirai, S., Kishi, K., Inagaki, T., Hara, I. Highdose-rate brachytherapy of a single implant with two fractions combined with external beam radiotherapy for hormone-naive prostate cancer. Int J Radiat Oncol Biol Phys 72, (2008). Received: May 1, 2010; Revised: June 10, 2010; Accepted: July 26, 2010
CyberKnife SBRT for Prostate Cancer
CyberKnife SBRT for Prostate Cancer Robert Meier, MD Swedish Radiosurgery Center Swedish Cancer Institute Seattle, WA 2017 ESTRO Meeting, Vienna Austria 5-year safety, efficacy & quality of life outcomes
More informationCYBERKNIFE SBRT FOR THE TREATMENT OF PROSTATE CANCER: 5 VS. 44 FRACTIONS THE PHILADELPHIA CYBERKNIFE CENTER EXPERIENCE
CYBERKNIFE SBRT FOR THE TREATMENT OF PROSTATE CANCER: 5 VS. 44 FRACTIONS THE PHILADELPHIA CYBERKNIFE CENTER EXPERIENCE Olusola Obayomi-Davies M.D. Philadelphia CyberKnife Center September 26 th, 2017 Disclosure
More informationNew Technologies for the Radiotherapy of Prostate Cancer
Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the
More informationLinac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery
Linac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery FILIPPO ALONGI MD Radiation Oncology & Radiosurgery Istituto Clinico
More informationStereotactic ablative body radiation for prostate cancer SABR
Stereotactic ablative body radiation for prostate cancer SABR John Armstrong. Sinead Callinan. Luke Rock. Beacon Hospital, Dublin, Ireland Low- Intermediate Risk Prostate Comparing treatment choices IMRT
More information1. CyberKnife Centers of San Diego, CA 2. Coast Urology La Jolla, CA 3. Sletten Cancer Center Great Falls, MT
Donald B. Fuller, M.D. 1, John Naitoh, M.D. 2, Mark Reilly, M.D. 3, Chad Lee, Ph.D 1. 1. CyberKnife Centers of San Diego, CA 2. Coast Urology La Jolla, CA 3. Sletten Cancer Center Great Falls, MT Typically,
More informationWould SBRT Hypofractionated Approach Be as Good? Then Why Bother With Brachytherapy?
Would SBRT Hypofractionated Approach Be as Good? Then Why Bother With Brachytherapy? Yasuo Yoshioka, MD Department of Radiation Oncology Osaka University Graduate School of Medicine Osaka, Japan Disclosure
More information20 Prostate Cancer Dan Ash
20 Prostate Cancer Dan Ash 1 Introduction Prostate cancer is a disease of ageing men for which the aetiology remains unknown. The incidence rises up to 30 to 40% in men over 80. The symptoms of localised
More informationProstate Cancer Appraisal Addendum: Stereotactic Body Radiation Therapy (SBRT)
Prostate Cancer Appraisal Addendum: Stereotactic Body Radiation Therapy (SBRT) The Institute for Clinical and Economic Review (ICER) has published appraisals on multiple management options for clinically-localized,
More informationPROSTATE CANCER TREATMENT
PROSTATE CANCER TREATMENT INFORMATION GUIDE Several effective treatment options exist today for men diagnosed with prostate cancer. Each man s particular cancer, overall health, age, and lifestyle will
More informationDepartment of Radiotherapy & Nuclear Medicine, National Cancer Institute, Cairo University, Cairo, Egypt.
Original article Res. Oncol. Vol. 12, No. 1, Jun. 2016:10-14 Dosimetric comparison of 3D conformal conventional radiotherapy versus intensity-modulated radiation therapy both in conventional and high dose
More informationHigh-Dose Rate Temporary Prostate Brachytherapy. Original Policy Date
MP 8.01.15 High-Dose Rate Temporary Prostate Brachytherapy Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return
More informationCyberKnife Radiotherapy For Localized Prostate Cancer: Rationale And Technical Feasibility
Open Access Article The authors, the publisher, and the right holders grant the right to use, reproduce, and disseminate the work in digital form to all users. Technology in Cancer Research & Treatment
More informationPROSTATE CANCER BRACHYTHERAPY. Kazi S. Manir MD,DNB,PDCR RMO cum Clinical Tutor Department of Radiotherapy R. G. Kar Medical College
PROSTATE CANCER BRACHYTHERAPY Kazi S. Manir MD,DNB,PDCR RMO cum Clinical Tutor Department of Radiotherapy R. G. Kar Medical College Risk categorization Very Low Risk Low Risk Intermediate Risk High Risk
More informationExternal Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer
External Beam Therapy for Low/Intermediate Risk Prostate Cancer Jeff Michalski, M.D. The Carlos A. Perez Distinguished Professor of Department of and Siteman Cancer Center Learning Objectives Understand
More informationSection: Therapy Effective Date: October 15, 2016 Subsection: Therapy Original Policy Date: December 7, 2011 Subject:
Last Review Status/Date: September 2016 Page: 1 of 10 Description High-dose rate (HDR) temporary prostate brachytherapy is a technique of delivering a high-intensity radiation source directly to the prostate
More informationRadiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008
Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators
More informationThree-year outcomes of 324 prostate carcinoma patients treated with combination high-dose-rate brachytherapy and intensity modulated radiation therapy
Original Article Three-year outcomes of 324 prostate carcinoma patients treated with combination high-dose-rate brachytherapy and intensity modulated radiation therapy Jekwon Yeh, Brandon Lehrich, Albert
More informationStereotactic Body Radiotherapy as Boost for Organ-confined Prostate Cancer
Technology in Cancer Research and Treatment ISSN 1533-0346 Volume 9, Number 6, December 2010 Adenine Press (2010) Stereotactic Body Radiotherapy as Boost for Organ-confined Prostate Cancer Stereotactic
More informationBRACHYTHERAPY FOR PROSTATE CANCER. Dr Brandon Nguyen MBBS(Hons), FRANZCR Radiation Oncologist, The Canberra Hospital
BRACHYTHERAPY FOR PROSTATE CANCER Dr Brandon Nguyen MBBS(Hons), FRANZCR Radiation Oncologist, The Canberra Hospital PROSTATE BRACHYTHERAPY Why brachytherapy? How do we do it? What are the results? Questions?
More informationPhase II study of FFF-SBRT in 5 fractions for low and intermediate risk prostate cancer
Phase II study of FFF-SBRT in 5 fractions for low and intermediate risk prostate cancer Ciro Franzese, G D Agostino, E Clerici, E Villa, A Tozzi, T Comito, C Iftode, AM Ascolese, F De Rose, S Pentimalli,
More informationHDR Brachytherapy: Results and Future Studies in Monotherapy
HDR Brachytherapy: Results and Future Studies in Monotherapy Nikolaos Zamboglou and Nikolaos Tselis Strahlenklinik Klinikum Offenbach - Germany Prostate Brachytherapy UK & Ireland Conference 2013 Comparison
More informationCLINICAL WORKSHOP IMAGE-GUIDED HDR BRACHYTHERAPY OF PROSTATE CANCER
CLINICAL WORKSHOP IMAGE-GUIDED HDR BRACHYTHERAPY OF PROSTATE CANCER Klinikum Offenbach Nucletron April 27 th 28 th, 2014 History HDR Protocols for Boost and Monotherapy, Results, Logistics and Practical
More informationModern Dose Fractionation and Treatment Techniques for Definitive Prostate RT
Modern Dose Fractionation and Treatment Techniques for Definitive Prostate RT Daniel J Bourgeois, III MD, MPH Board Certified Radiation Oncologist Southeast Louisiana Radiation Oncology Group (SLROG) Disclosures
More informationPatient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer
Bhattasali et al. Radiation Oncology 2014, 9:52 RESEARCH Open Access Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer Onita Bhattasali 1,
More informationDose escalation with external beam therapy for
Rapid Communication Reduction in Patient-reported Acute Morbidity in Prostate Cancer Patients Treated With 81-Gy Intensity-modulated Radiotherapy Using Reduced Planning Target Volume Margins and Electromagnetic
More informationDescription. Section: Therapy Effective Date: October 15, 2015 Subsection: Therapy Original Policy Date: December 7, 2011 Subject:
Last Review Status/Date: September 2015 Page: 1 of 14 Description High-dose rate (HDR) temporary prostate brachytherapy is a technique of delivering a high-intensity radiation source directly to the prostate
More informationStereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates ( 50 cm 3 )
Janowski et al. Radiation Oncology 2014, 9:241 RESEARCH Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates ( 50 cm 3 ) Einsley Janowski 1, Leonard N Chen 1, Joy
More informationJean Pouliot, PhD Professor and Vice Chair, Department of Radiation Oncology, Director of Physics Division
IMRT / Tomo / VMAT / Cyberknife / HDR Brachytherapy: Jean Pouliot, PhD Professor and Vice Chair, Department of Radiation Oncology, Director of Physics Division Should Choices be Based on Dosimetric and
More informationProstate SBRT Heterogeneous Dose Distribution: Rationale, Methods, Outcomes and Future Direction: 2017 Update
Prostate SBRT Heterogeneous Dose Distribution: Rationale, Methods, Outcomes and Future Direction: 2017 Update DONALD B. FULLER, M.D. RADIATION ONCOLOGIST GENESIS HEALTHCARE Disclosure & Disclaimer The
More informationEORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924
EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without
More informationName of Policy: High-Dose Rate Temporary Prostate Brachytherapy
Name of Policy: High-Dose Rate Temporary Prostate Brachytherapy Policy #: 024 Latest Review Date: June 2014 Category: Therapy Policy Grade: C Background/Definitions: As a general rule, benefits are payable
More informationOPTIMIZATION OF COLLIMATOR PARAMETERS TO REDUCE RECTAL DOSE IN INTENSITY-MODULATED PROSTATE TREATMENT PLANNING
Medical Dosimetry, Vol. 30, No. 4, pp. 205-212, 2005 Copyright 2005 American Association of Medical Dosimetrists Printed in the USA. All rights reserved 0958-3947/05/$ see front matter doi:10.1016/j.meddos.2005.06.002
More informationExternal Beam Radiotherapy for Prostate Cancer
External Beam Radiotherapy for Prostate Cancer Chomporn Sitathanee, Radiation Oncology Unit Ramathibodi Hospital, Mahidol University Roles of RT in prostate cancer Definitive RT; intact prostate Post radical
More informationHDR vs. LDR Is One Better Than The Other?
HDR vs. LDR Is One Better Than The Other? Daniel Fernandez, MD, PhD 11/3/2017 New Frontiers in Urologic Oncology Learning Objectives Indications for prostate brachytherapy Identify pros/cons of HDR vs
More informationLDR Monotherapy vs. HDR Monotherapy
Abstract No. 1234 LDR Monotherapy vs. HDR Monotherapy Is it time for LDR to retire? Gerard Morton 2 LDR Seed Brachytherapy First 2000 LDR patients from BCCA Low and Intermediate Risk LDR Implant Morris
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationAlan Katz Josephine Kang
Radiation Oncology This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon. Stereotactic body radiotherapy
More informationCyberKnife Radiosurgery for Prostate Cancer
Technology in Cancer Research and Treatment ISSN 1533-0346 Volume 9, Number 5, October 2010 Adenine Press (2010) CyberKnife Radiosurgery for Prostate Cancer www.tcrt.org Treatment of prostate cancer with
More informationHypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
Ju et al. Radiation Oncology 2013, 8:30 RESEARCH Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer Andrew W Ju 1, Hongkun Wang 2, Eric K Oermann
More informationTechnological Advances in Radiotherapy for the Treatment of Localized Prostate Cancer - A Systematic Review
Technological Advances in Radiotherapy for the Treatment of Localized Prostate Cancer - A Systematic Review Jayatissa R.M.G.C.S.B. (B.Sc.) Department of Radiography/Radiotherapy, Faculty of Allied Health
More informationResearch Article Implant R100 Predicts Rectal Bleeding in Prostate Cancer Patients Treated with IG-IMRT to 45 Gy and Pd-103 Implant
Radiotherapy, Article ID 130652, 6 pages http://dx.doi.org/10.1155/2014/130652 Research Article Implant R100 Predicts Rectal Bleeding in Prostate Cancer Patients Treated with IG-IMRT to 45 Gy and Pd-103
More informationHigh dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients
High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients Tselis et al. Tselis et al. Radiation Oncology 213, 8:115
More informationSalvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK
Salvage HDR Brachytherapy Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Disclosures Still No financial disclosures! Limited personal experience of HDR Brachy as salvage option
More informationStatistical Analysis and Volumetric Dose for Organ at Risk of Prostate Cancer
The African Review of Physics (2013) 8:0063 477 Statistical Analysis and Volumetric Dose for Organ at Risk of Prostate Cancer F. Assaoui¹,*, A. Bazine² and T. Kebdani³ ¹ Medical Physics Unit, Radiotherapy
More informationSalvage low-dose-rate 125 I partial prostate brachytherapy after dose-escalated external beam radiotherapy
Case report Salvage low-dose-rate 125 I partial prostate brachytherapy after dose-escalated external beam radiotherapy Lynn Chang, MD 1, Mark K. Buyyounouski, MD, MS 2 Case Report 1 Department of Radiation
More informationPACE Study. Hypofractionation 17/12/2014. Traditional Model of Fractionation 200 Response. What s the fraction sensitivity of prostate cancer?
0 0 17/12/2014 2 Outline of today s talk PACE Study Background rationale for PACE? Dr Nicholas van As A bit about technology. What is PACE? How can I get involved? London: 1 December 2014 250 Hypofractionation
More informationIntensity Modulated Radiotherapy (IMRT) of the Prostate
Medical Policy Manual Medicine, Policy No. 137 Intensity Modulated Radiotherapy (IMRT) of the Prostate Next Review: August 2018 Last Review: November 2017 Effective: December 1, 2017 IMPORTANT REMINDER
More informationTrina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April
Trina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April 17, 2016 Discuss permanent prostate brachytherapy and
More informationDosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer
Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer Tan Chek Wee 15 06 2016 National University Cancer Institute, Singapore Clinical Care Education Research
More informationVital role of volume and number of needles in HDR brachytherapy (HDR-BT) of prostate cancer
Original article Clinical Investigations Vital role of volume and number of needles in HDR brachytherapy (HDR-BT) of prostate cancer Adam Chichel/, MD, Marek Kanikowski, MD, Janusz Skowronek, MD, PhD,
More informationCLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
More informationPropensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer
J Radiat Oncol (2016) 5:187 195 DOI 10.1007/s13566-015-0237-0 ORIGINAL RESEARCH Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer Caspian Oliai 1 &
More informationProstate Cancer. 3DCRT vs IMRT : Hasan Murshed
Prostate Cancer 3DCRT vs IMRT : the second debate Hasan Murshed Take home message IMRT allows dose escalation. Preliminary data shows IMRT technique improves cancer control while keeping acceptable morbidity
More informationThe clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer Health technology description
In response to an enquiry from the Scottish Radiotherapy Advisory Group Number 37 June 2011 The clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer Health technology
More informationCyberKnife Monotherapy for Prostate Cancer
C H A P T E R 29 CyberKnife Monotherapy for Prostate Cancer Clinton A. Medbery Marianne M. Young Astrid E. Morrison J. Stephen Archer Maximian F. D Souza Cindy Parry Abstract The purpose of our planned
More informationIrreversible Electroporation for the Treatment of Recurrent Prostate Cancer
Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer after prostatectomy, radiation therapy and HiFU R. Schwartzberg, E. Günther, N. Klein, S. Zapf, R. El-Idrissi, J. Cooper, B.
More informationMEDICAL POLICY SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER
MEDICAL POLICY SUBJECT: BRACHYTHERAPY OR PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More informationDosimetric impacts of endorectal balloon in CyberKnife stereotactic body radiation therapy (SBRT) for early-stage prostate cancer
Received: 31 October 2016 Revised: 24 January 2017 Accepted: 7 February 2017 DOI: 10.1002/acm2.12063 RADIATION ONCOLOGY PHYSICS Dosimetric impacts of endorectal balloon in CyberKnife stereotactic body
More informationHigh Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
More informationTRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY
TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY 1 TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY BRENDAN CAREY, MD TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY 2 TRANSRECTAL ULTRASOUND-GUIDED
More informationProstate Cancer Treatment
Scan for mobile link. Prostate Cancer Treatment Prostate cancer overview Prostate cancer is the most common form of cancer in American men, most prevalent in men over age 65 and fairly common in men 50-64
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationor low dose rate (LDR), brachytherapy
High dose rate brachytherapy for prostate cancer: Current techniques and applications to varying disease presentations Daniel J. Krauss, MD High dose rate (HDR) brachytherapy has been an option for managing
More informationSTUDY CHAIR. Arica Hirsch, MD Advocate Lutheran General Hospital 1700 Luther Lane, Suite 204 Park Ridge, IL 60068
PROSPECTIVE EVALUATION OF CYBERKNIFE AS MONOTHERAPY OR BOOST STEREOTACTIC BODY RADIOTHERAPY FOR INTERMEDIATE OR HIGH RISK LOCALIZED PROSTATE CANCER: AN OBSERVATIONAL STUDY STUDY CHAIR Arica Hirsch, MD
More informationBRACHYTHERAPY FOR PATIENTS WITH PROSTATE CANCER: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update
BRACHYTHERAPY FOR PATIENTS WITH PROSTATE CANCER: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update Table of Contents Data Supplement 1: Additional Evidence Table(s) Table
More informationOriginal articles. Abstract. Purpose
Original article Original articles Correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high-dose-rate brachytherapy (HDR-BT) as a boost Adam
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationPotency preservation following stereotactic body radiation therapy for prostate cancer
Obayomi-Davies et al. Radiation Oncology 2013, 8:256 RESEARCH Open Access Potency preservation following stereotactic body radiation therapy for prostate cancer Olusola Obayomi-Davies 1,LeonardNChen 1,AditiBhagat
More informationProstate Cancer Dashboard
Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment
More informationStereotactic body radiation therapy in oligometastatic patient with lymph node recurrent prostate cancer: a single centre experience.
Stereotactic body radiation therapy in oligometastatic patient with lymph node recurrent prostate cancer: a single centre experience. Elisabetta Ponti MD, Gianluca Ingrosso MD, Alessandra Carosi PhD, Luana
More informationThe New ICRU/GEC ESTRO Report in Clinical Practice. Disclosures
The New ICRU/GEC ESTRO Report in Clinical Practice Christian Kirisits, MSc, PhD; Richard Pötter, MD Medical University of Vienna, Vienna, Austria On behalf of the Committee: B. Erickson, C. Haie Meder,
More informationHIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER
0022-5347/01/1663-0876/0 THE JOURNAL OF UROLOGY Vol. 166, 876 881, September 2001 Copyright 2001 by AMERICAN UROLOGICAL ASSOCIATION, INC. Printed in U.S.A. HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED
More informationA schematic of the rectal probe in contact with the prostate is show in this diagram.
Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview
More informationEvaluation of Normal Tissue Complication Probability and Risk of Second Primary Cancer in Prostate Radiotherapy
Evaluation of Normal Tissue Complication Probability and Risk of Second Primary Cancer in Prostate Radiotherapy Rungdham Takam Thesis submitted for the degree of Doctor of Philosophy in The School of Chemistry
More informationHypofractionation for Prostate Cancer: the Present Luca Incrocci, MD PhD
Hypofractionation for Prostate Cancer: the Present Luca Incrocci, MD PhD Professor of Genito-Urinary Radiotherapy Erasmus MC Cancer Institute Rotterdam, The Netherlands Themadag Prostaatcarcinoom 15 maart
More informationMEDICAL POLICY. SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: BRACHYTHERAPY OR PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy
More informationJure Murgic 1, Matthew H Stenmark 1, Schuyler Halverson 1, Kevin Blas 1, Felix Y Feng 1,2 and Daniel A Hamstra 1,3*
Murgic et al. Radiation Oncology 2012, 7:127 RESEARCH Open Access The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for
More informationCorporate Medical Policy
Corporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_the_prostate
More informationA PRACTICAL METHOD TO ACHIEVE PROSTATE GLAND IMMOBILIZATION AND TARGET VERIFICATION FOR DAILY TREATMENT
PII S0360-3016(01)02663-3 Int. J. Radiation Oncology Biol. Phys., Vol. 51, No. 5, pp. 1431 1436, 2001 Copyright 2001 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/01/$ see front
More informationSRO Tutorial: Prostate Cancer Clinics
SRO Tutorial: Prostate Cancer Clinics May 7th, 2010 Daniel M. Aebersold Klinik und Poliklinik für Radio-Onkologie Universität Bern, Inselspital Is cure necessary in those in whom it may be possible, and
More informationRadiation Dose Escalation for Localized Prostate Cancer
Radiation Dose Escalation for Localized Prostate Cancer Intensity-Modulated Radiotherapy Versus Permanent Transperineal Brachytherapy William W. Wong, MD 1 ; Sujay A. Vora, MD 1 ; Steven E. Schild, MD
More informationEmbracing Technology & Timing of Salvage Hormones
Embracing Technology & Timing of Salvage Hormones Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology Sunnybrook Health Sciences Centre University of Toronto Us Too, Brampton October
More informationClinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate
Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate Reference: NHS England B01X09 First published: March 2016 Prepared by NHS England Specialised Services Clinical
More informationINTENSITY MODULATED RADIATION THERAPY: Next Generation 3-D CRT or Distinct Form of RT?
INTENSITY MODULATED RADIATION THERAPY: Next Generation 3-D CRT or Distinct Form of RT? Three dimensional conformal radiation therapy (3D-CRT) uses a uniform dose of radiation where the dose distribution
More informationHypofractionated Stereotactic Body Radiotherapy in Low-Risk Prostate Adenocarcinoma
Hypofractionated Stereotactic Body Radiotherapy in Low-Risk Prostate Adenocarcinoma Preliminary Results of a Multi-Institutional Phase 1 Feasibility Trial Sean M. McBride, MD 1 ; Douglas S. Wong, MD, PhD,
More informationJOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 6, NUMBER 2, SPRING 2005
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 6, NUMBER 2, SPRING 2005 Advantages of inflatable multichannel endorectal applicator in the neo-adjuvant treatment of patients with locally advanced
More informationAn Update on Radiation Therapy for Prostate Cancer
An Update on Radiation Therapy for Prostate Cancer David C. Beyer, MD, FACR, FACRO, FASTRO Arizona Oncology Services Phoenix, Arizona Objectives Review significant new data Identify leading trends in PCa
More informationIntensity Modulated Radiation Therapy (IMRT)
Intensity Modulated Radiation Therapy (IMRT) Policy Number: Original Effective Date: MM.05.006 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/01/2017 Section: Radiology
More informationBiodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer Radiotherapy
More informationInnovazioni tecnologiche in Radioterapia" Sergio Fersino Radioterapia Oncologica
Innovazioni tecnologiche in Radioterapia" Sergio Fersino Radioterapia Oncologica 2014 HYPOFRACTIONATION & PROSTATE CANCER HYPOFRACTIONATION & PROSTATE CANCER: TECHNOLOGY: HIGH CONFORMAL DOSE & IMAGING
More informationImproving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 14, NUMBER 5, 2013 Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife
More informationRole of Belly Board Device in the Age of Intensity Modulated Radiotherapy for Pelvic Irradiation
Role of Belly Board Device in the Age of Intensity Modulated Radiotherapy for Pelvic Irradiation 2017 AAMD 42 nd Annual Meeting Neil C. Estabrook, MD 6 / 14 / 2017 7/5/2017 1 Conflicts of Interest None
More informationNew research in prostate brachytherapy
New research in prostate brachytherapy Dr Ann Henry Associate Professor in Clinical Oncology University of Leeds and Leeds Cancer Centre PIVOTAL boost opening 2017 To evaluate - The benefits of pelvic
More informationFuture Directions in Prostate Cancer: The Case for Protons. John J. Coen, MD Helen & Harry Gray Cancer Center
Future Directions in Prostate Cancer: The Case for Protons John J. Coen, MD Helen & Harry Gray Cancer Center November 14, 2012 Protons and prostate cancer Early proton experience at the MGH The case for
More informationRadiotherapy Advances
Radiotherapy Advances Not Radiotherapy Principles IMRT IGRT Image Fusion Planning Introduction IMRT = Intensity Modulated RadioTherapy Restriction: IMRT with photon beams IMRT: Highly conformal technique
More information